ViroMed to strengthen its global presence with
former US FDA reviewer and phytomedicine expert recently joined
SEOUL, Korea - ViroMed (KOSDAQ 084990), a novel
medicine developing biotech company, announced on 28th July that Dr.
Jun Tae Park, former US FDA reviewer, and Dr. Miwon Sohn, former Senior Vice President of phytotherapeutics
research & development at Dong-A ST have recently joined the company to become
part of the enterprise-wide efforts to advance the company’s out-licensing activities
and its entry into the global market.
President, Dr. Park will direct LARA (Licensing and Regulatory Affairs) Unit supervising
out-licensing and regulatory issues in order to promote successful licensing
and entry into advanced markets.
Until recently, he has served as a reviewer at the US FDA
where he worked for over 11 years in charge of reviewing BLA/NDA and conducting
scientific research for evaluation of the manufacturing process and product
quality assessment for biopharmaceutical products. Before joining the FDA, he
worked for Alpha-Beta Technology, Inc. and US Department of Defense (DoD) after
he earned his doctorate in 1990 in the US.
Dr. Sohn will serve
as Chief of Phytotherapeutics Business Unit after having worked as Head of Pharmaceutical Product Research
Laboratories and as Senior Vice President & Head of Research Planning and
Management Department, both at Dong-A ST. She is one of the top phytomedicine
experts with experiences in phytotherapeutics research and product development,
who played a key role in developing mega blockbuster phytomedicines in Korea.
She also served as Director of the Global Botanical Drug Development Center by then the
Ministry of Knowledge Economy (Ministry of Trade, Industry and Energy now) promoting
the entry into overseas markets of phytomedicines under development. She is also academically
active and has been Adjunct Professor
at School of Natural Science,
Sangmyung University and School of Pharmacy, SungKyunKwan University
“We expect Dr. Park to provide a direction
that is in line with the US FDA for our new drug development process, which
encompasses biologics manufacturing, clinical development, product evaluation,
and BLA. Together with him, we are expecting to further strengthen our
capabilities and boost our potential to successfully license out our technology
and get regulatory approval. He has a vast network he obtained while doing his
work at the FDA, and it certainly will help enhance our business performance
including out-licensing,” ViroMed CEO Yongsoo Kim pointed out with confidence.
He went on to say that “with ViroMed’s unparalleled experience in developing
phytotherapeutics and Dr. Sohn’s experience in breaking into overseas markets, we
will be able to both solidify and diversify our phytotherapeutics business while
actively promoting our presence in the global market.” The two top experts are
expected to play a critical role for ViroMed making a huge leap forward as a
global biotech company.